GlassScriptPhysician profile
Meeradevi Sudarsanan
NPI 1407282098
$1,060.94
in general payments reported to CMS, 2019-2025
10 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.25 · 2023: $245 · 2024: $439 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $228.67 | 2021-2025 | |
| Kyowa Kirin, INC. | $139.99 | 2025 | |
| Neurelis, INC. | $123.58 | 2023 | Valtoco |
| Neurocrine Biosciences, INC. | $114.86 | 2024 | |
| Gilead Sciences, INC. | $101.42 | 2023-2025 | Livdelzi, Epclusa |
| Janssen Biotech, INC. | $88.75 | 2024 | Tremfya, Stelara |
| Ucb, INC. | $82.87 | 2024 | Nayzilam |
| Corcept Therapeutics | $77.70 | 2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $73.81 | 2023 | Lokelma |
| La Jolla Pharmaceutical Company | $29.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meeradevi Sudarsanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.